Leukemic stem cells modulate the bone marrow microenvironment

ESH eLearning, Bonnet Dominique, 219256

Is transplant needed to cure Ph+ ALL in patients who achieve MRD negativity? - No

ESH eLearning, Farhad Ravandi-Kashani, 219257

An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias

ESH eLearning, Arnold Ganser, 226249

The devastating effects of relapsed or refractory AML

ESH eLearning, Arnold Ganser, 226250

From bench to the bedside: understanding the genetic changes in AML

ESH eLearning, Arnold Ganser, 226251

Finding the right targets for CAR T-cell therapy in AML

ESH eLearning, Arnold Ganser, 226252

Midostaurin: the first drug to receive approval for AML since 2000

ESH eLearning, Arnold Ganser, 226253

Overcoming the issues with clinical trial recruitment

ESH eLearning, Arnold Ganser, 226254

Transplantation clinical trial network to build available prospective studies on AML

ESH eLearning, Charles Craddock, 226255

Current understandings of ALL approaches

ESH eLearning, Charles Craddock, 226256

Challenges with the identification of ALL subtypes

ESH eLearning, Charles Craddock, 226257

Immunotherapies for the treatment of AML

ESH eLearning, Christoph Röllig, 226264

Managing AML in elderly patients

ESH eLearning, Christoph Röllig, 226265

Biological rationales when determining AML therapies

ESH eLearning, Christoph Röllig, 226266

Targeting IDH mutations for the treatment of AML

ESH eLearning, Eytan Stein, 226267

Toxicity profiles of IDH inhibitors: are they as intimidating as they seem?

ESH eLearning, Eytan Stein, 226268

Primary and secondary resistance in AML

ESH eLearning, Eytan Stein, 226269

Encouraging patients to participate in AML trials

ESH eLearning, Eytan Stein, 226270

The latest clinical trials into novel AML therapies

ESH eLearning, Eytan Stein, 226271

The complications of treating elderly patients with AML

ESH eLearning, Gail Roboz, 226272

Managing relapse in AML: the role of MRD

ESH eLearning, Gail Roboz, 226273

Involving the patient is a key part of cancer treatment

ESH eLearning, Mark Levis, 226280

CAR T-cell therapy and ALL: the current landscape

ESH eLearning, Noelle Frey, 226281

The CAR T-cell therapy race

ESH eLearning, Noelle Frey, 226282

The importance of MRD assessment in all phases of ALL treatment

ESH eLearning, Noelle Frey, 226283

Next-generation methodologies: the future for MRD monitoring in ALL?

ESH eLearning, Wendy Stock, 226284

Emerging novel approaches for ALL: inotuzumab ozogamicin

ESH eLearning, Wendy Stock, 226285

Support systems are a crucial factor in ALL treatment

ESH eLearning, Wendy Stock, 226286

Bone marrow transplant in red cell disorders

ESH eLearning, eliane Gluckman, 219043

Sickle cell disease pathophysiology

ESH eLearning, Jacques Elion, 219038

Thalassaemias

ESH eLearning, Maria Domenica Cappellini, 219039

Malaria and red cell disorders

ESH eLearning, Michael Lanzer, 219040

Epidemiology of red cell disorders

ESH eLearning, Frédéric B. Piel, 219041

Red cell senescence and storage lesions

ESH eLearning, Giel Bosman, 219042

Erythroid niche and erythroblast maturation

ESH eLearning, Mohandas Narla, 219034

Epigenetics in erythropoiesis

ESH eLearning, Gordon D. Ginder, 219035

Heme synthesis and iron metabolism

ESH eLearning, Laurent Gouya, 219036

Red cells and oxidative stress

ESH eLearning, Lucia De Franceschi, 219037

Richter transformation in the elderly patient:molecular origin and new strategies for improved therapies

ESH eLearning, Davide Rossi, 212197

Targeting the DNA Damage Response in high-risk lymphoma: biology and insights for future, less toxic approaches of therapy

ESH eLearning, Christian REINHARDT, 212198

Double hit and other types of high-risk lymphoma:molecular features and optimal management in the elderly patient

ESH eLearning, Paul Hamlin, 212199

Biology of AML at older age

ESH eLearning, Terrence N. Wong, 212185

Therapeutic management of the so-called “fit” older patient with AML

ESH eLearning, Bob Löwenberg, 212186

Management of the unfit patient with AML

ESH eLearning, Gert Ossenkoppele, 212187

The older patient with ALL

ESH eLearning, Hervé Dombret, 212188

Alloegeneic stem cell transplantation at older age

ESH eLearning, Nicolaus Kröger, 212189

Clonal evolution of multiple myeloma

ESH eLearning, Nikhil Munshi, 212190

MGUS and MGUS transition to myeloma, what do we need to do?

ESH eLearning, Irene Ghobrial, 212191

Multiple myeloma in the elderly, a particular challenge in light of numerous novel agents.

ESH eLearning, Jesús F. San-Miguel, 212192

Clonal evolution in malignant lymphoma

ESH eLearning, Jude FITZGIBBON, 212193

Management of indolent lymphoma in the elderly patient

ESH eLearning, Loretta Nastoupil, 212194

Management of comorbidity and specific adverse events in the era of novel kinase inhibitors (ibrutinib, idelalisib, venetoclax) for lymphoid malignancies

ESH eLearning, Farrukh Awan, 212195

Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma

ESH eLearning, Loretta Nastoupil, 212196

DNA damage, a driving force of aging

ESH eLearning, Björn Schumacher, 212174

Clonal hematopoiesis

ESH eLearning, Benjamin Ebert, 212175

Clonal hematopoiesis

ESH eLearning, George Vassiliou, 212176

Selection of TP53 mutant clones following chemotherapy

ESH eLearning, Terrence N. Wong, 212177

Aging stem cells and stress

ESH eLearning, Michael Milsom, 212178

Anemia at older age

ESH eLearning, Nancy Berliner, 212179

Microenvironment and MDS

ESH eLearning, Rebekka Schneider, 212180

Biology of MDS

ESH eLearning, Benjamin Ebert, 212181

Management of high grade MDS

ESH eLearning, Pierre Fenaux, 212182

Management of CMML and other MDS/MPN entities

ESH eLearning, Raphael Itzykson, 212183

Assessing the aging individual with hematologic disorders: How geriatric assessment can define the fitness of an older patient

ESH eLearning, Tanya Wildes, 212184

The pathology of marginal zone lymphomas

ESH eLearning, German Ott, 210034

Marginal zone lymphoma: biology and molecular genetics

ESH eLearning, Ming Qing Du, 210035

Marginal zone lymphoma. Prognostic models.

ESH eLearning, Carlos Montalban, 210036

Clinical aspects

ESH eLearning, Catherine Thieblemont, 210037

Treatment of splenic marginal zone lymphoma

ESH eLearning, Barbara Kiesewetter, 210038

Treatment of nodal marginal zone lymphoma

ESH eLearning, Catherine Thieblemont, 210039

Treatment of MALT lymphoma

ESH eLearning, Emanuele Zucca, 210040

Novel targeted therapies in CL - Ibrutinib

ESH eLearning, John Gribben, 210025

Idelalisib

ESH eLearning, Michael J. Keating, 210026

Venetoclax

ESH eLearning, Peter Hillmen, 210027

Follicular lymphoma; from genetics to pathogenesis

ESH eLearning, Riccardo Dalla-Favera, 210028

Clonal evolution of follicular lymphoma

ESH eLearning, Michael R. Green, 210029

Integrating molecular diagnostics for improved patient stratification in follicular lymphoma

ESH eLearning, Oliver Weigert, 210030

Advanced stage patient, first line

ESH eLearning, Christian BUSKE, 210031

Treatment of follicular lymphoma (FL): Salvage therapy

ESH eLearning, Vincent Ribrag, 210032

New agents

ESH eLearning, Gilles Salles, 210033

Micro RNA dysregulation to identify targets for therapy in hematopoietic malignancies

ESH eLearning, Carlo M. Croce, 210019

Genetic portrait of CLL

ESH eLearning, Cathy Wu, 210020

Predictive biomarkers in CLL

ESH eLearning, Davide Rossi, 210021

FCR

ESH eLearning, Michael J. Keating, 210022

BR

ESH eLearning, Olivier Tournilhac, 210023

Chlorambucil plus anti-CD20 MoAb

ESH eLearning, Valentin Goede, 210024

Myeloma Hub

ESH eLearning, ESH , 204612

iCMLf Prize talk

ESH eLearning, Jerry Radich, 205141

John Goldman Prize Talk

ESH eLearning, Tim Hughes, 205140

Janet Rowley Prize talk

ESH eLearning, Mhairi Copland, 205142

The need for collaboration amongst hospitals: learning from RATIFY

ESH eLearning, Miguel Sanz, 204652

Why are new molecules typically combined with standard chemotherapy?

ESH eLearning, Miguel Sanz, 204653

Integrating midostaurin into FLT3 positive AML treatment

ESH eLearning, Miguel Sanz, 204654

The challenges of using kinase inhibitors for AML treatment

ESH eLearning, Mark Levis, 204668

Venetoclax for elderly AML patients

ESH eLearning, Mark Levis, 204669

The drugs being used to treat newly diagnosed AML patients

ESH eLearning, Mark Levis, 204670

Mimetics: the future of AML treatment?

ESH eLearning, Andrew Wei, 204684

Highly targeted medication for AML

ESH eLearning, Andrew Wei, 204685

Translational research in Berlin to improve AML treatment outcomes

ESH eLearning, Lars Bullinger, 204700

Reassuring patients with AML

ESH eLearning, Lars Bullinger, 204701